Hand holding cannabis extract. (Source: Adobe Stock. Generated by AI)
  • Tilray Medical, a division of cannabis powerhouse Tilray Brands (TSX:TLRY), has partnered with Molteni, an Italian pharmaceutical firm focused on pain therapies and substance dependence, to broaden the availability of its cannabis extracts across Italy
  • Tilray Brands is a cannabis, beverage, wellness and entertainment company supporting more than 40 brands in more than 20 countries
  • Tilray stock has given back 48.03 per cent year-over-year and 93.28 per cent since May 2021

Tilray Medical, a division of cannabis powerhouse Tilray Brands (TSX:TLRY), has partnered with Molteni, a top Italian pharmaceutical firm focused on pain therapies and substance dependence, to broaden the availability of its cannabis extracts across Italy.

This content has been prepared as part of a partnership with Tilray Brands Inc., and is intended for informational purposes only.

Under the partnership, Tilray Medical subsidiary, FL Group, will provide medical cannabis education throughout Molteni’s network of pharmaceutical, scientific and medical professionals in Italy.

Founded in 1892 and headquartered in Florence, Molteni maintains operations in more than 40 countries and benefits from in-house manufacturing, research and development, regulatory, supply chain and commercial capabilities, opening the door for future partnerships with Tilray down the line.

The new partnership complements Tilray’s existing operations in Italy, in addition to presences in Germany, Portugal, Poland and the United Kingdom, with European cannabis revenue growing by 112 per cent in fiscal 2025.

Leadership insights

“This partnership reflects our commitment to advancing patient care through strategic collaboration,” Rajnish Ohri, Tilray Brands’ Managing Director, International, said in Wednesday’s news release. “By combining FL Group’s regulatory and distribution capabilities with Molteni’s scientific leadership, we are not only expanding access to high-quality, EU-GMP certified cannabis therapies for patients across Italy but also prioritizing medical cannabis education for pain therapies. Through Molteni’s extensive network of healthcare professionals, we aim to empower practitioners with the knowledge and resources needed to support patients seeking effective pain management solutions.”

About Tilray Brands

Tilray Brands is a cannabis, beverage, wellness and entertainment company supporting more than 40 brands in more than 20 countries.

Tilray stock (TSX:TLRY) las traded at C$1.32. The cannabis stock has given back 48.03 per cent year-over-year and 93.28 per cent since May 2021.

Join the discussion: Find out what everybody’s saying about this Canadian cannabis stock on the Tilray Brands Inc. Bullboard and check out the rest of Stockhouse’s stock forums and message boards.

Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.


More From The Market Online

@ the Bell: Stocks rebound into the weekend

The TSX added 0.53% on Friday, ending the week with a 2.17% loss, as investors rekindled risk-on sentiment thanks to a lower oil price.
Oracle jumped 7% on AI cloud demand, lifting the TSX, Dow and Nasdaq, while OpenAI and Anthropic flagged AI risks ahead.

Market Open: Oracle Soars 7% as Markets Rally Despite Oil Above $98 | Sep 11th

Oracle jumped 7% on AI cloud demand, lifting the TSX, Dow and Nasdaq, while OpenAI and Anthropic flagged AI risks ahead.

Promising copper play cleared for solo listing

Copper explorer Blade Resources receives a green light to list its shares on the Canadian Securities Exchange on Monday, September 14th.

StockTalk | Cannabis Report: M&A sparks, insider buys and revenue highs

Curaleaf (TSX:CURA) continues to tout the value it would bring to Aurora Cannabis shareholders, should they agree to an acquisition.